Genethon and WhiteLab Genomics Join Forces to Enhance Gene Therapy Through Artificial Intelligence
The alliance will harness the power of artificial intelligence to accelerate development of innovative gene therapies.
As part of this partnership, Genethon teams will use WhiteLab Genomics Catalyst
TM platform to develop new capsids, or vectors, which are essential components for gene therapy products.
While several gene therapy products have already obtained market authorization for the treatment of rare and common diseases, which demonstrates the efficacy of this approach for conditions considered to be incurable, development of these complex therapies continues to face major scientific and technical hurdles. Many vectors used in gene therapy are derivatives of adeno-associated viruses (AAV). Their use has limitations: natural immunization of 30% to 40% of the population and difficulty targeting a specific tissue. As a result, extremely large quantities of vectors are necessary